Biodexa Pharmaceticals (BDRX) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Biodexa Pharmaceticals stock (BDRX) is currently trading at $0.66. Biodexa Pharmaceticals PS ratio (Price-to-Sales) is 0.58. Analyst consensus price target for BDRX is $178.30. WallStSmart rates BDRX as Sell.
- BDRX PE ratio analysis and historical PE chart
- BDRX PS ratio (Price-to-Sales) history and trend
- BDRX intrinsic value — DCF, Graham Number, EPV models
- BDRX stock price prediction 2025 2026 2027 2028 2029 2030
- BDRX fair value vs current price
- BDRX insider transactions and insider buying
- Is BDRX undervalued or overvalued?
- Biodexa Pharmaceticals financial analysis — revenue, earnings, cash flow
- BDRX Piotroski F-Score and Altman Z-Score
- BDRX analyst price target and Smart Rating
Biodexa Pharmaceticals
📊 No data available
Try selecting a different time range
Smart Analysis
Biodexa Pharmaceticals (BDRX) · 6 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/sales, price/book, institutional own.. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Biodexa Pharmaceticals (BDRX) Key Strengths (3)
Paying less than $1 for every $1 of annual revenue
Trading below book value, meaning the market prices it less than net assets
52.28% held by institutions, strong professional interest
Supporting Valuation Data
Biodexa Pharmaceticals (BDRX) Areas to Watch (3)
Company is destroying shareholder value
Revenue declining -64.10%, a shrinking business
Micro-cap company with very limited liquidity and high volatility
Biodexa Pharmaceticals (BDRX) Detailed Analysis Report
Overall Assessment
This company scores 33/100 in our Smart Analysis, earning a F grade. Out of 6 metrics analyzed, 3 register as strengths (avg 9.3/10) while 3 fall into concern territory (avg 1.0/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Sales, Price/Book, Institutional Own.. Valuation metrics including Price/Sales (0.58), Price/Book (0.04) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Revenue Growth, Market Cap. Growth concerns include Revenue Growth at -64.10%, which may limit upside. Profitability pressure is visible in Return on Equity at -61.80%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -61.80% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -64.10% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. Strengths and concerns are roughly balanced. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Revenue Growth are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
BDRX Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
BDRX's Price-to-Sales ratio of 0.58x sits near its historical average of 0.58x (0th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 1% below its historical high of 0.58x set in Feb 2026, and -1% above its historical low of 0.58x in Feb 2026.
WallStSmart Analysis Synopsis
Data-driven financial summary for Biodexa Pharmaceticals (BDRX) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Biodexa Pharmaceticals operates as a stable business with moderate growth and solid fundamentals. Revenue reached 83,000 with 64% decline year-over-year. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Debt-to-equity ratio of 0.04 indicates a conservative balance sheet with 4M in cash.
Spending 2006% of revenue (2M) on R&D, reinforcing its commitment to innovation and future growth.
Revenue contracted 64% YoY. Worth determining whether this is cyclical or structural.
Free cash flow is -3M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Biodexa Pharmaceticals.
Bottom Line
Biodexa Pharmaceticals offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Biodexa Pharmaceticals(BDRX)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Biodexa Pharmaceuticals Plc, a drug delivery technology company, focuses on the bio-delivery and biodistribution of medicines in the United Kingdom, rest of Europe, and internationally. The company is headquartered in Cardiff, the United Kingdom.